Adagene Announces $25 Million Strategic Investment from Sanofi to Advance Muzastotug (ADG126) and Expand SAFEbody® Collaboration

On July 1, Adagene announced that Sanofi will make a strategic investment in the company and launch the third SAFEbody® development project under the SAFEbody® safety antibody collaboration framework between the two parties.

ScreenshotSource:Adagene Official WeChat

According to the agreement,Sanofi to Make Strategic Investment of Up to $25 Million in Adagene, The funds will be mainly used to advance product development, with a focus on supportingAnti-CTLA-4 SAFEbody® Muzastotug（ADG126）In microsatellite-stable colorectal cancer（MSS CRC）Phase Ⅱ Clinical Trial in China.

To further evaluate the clinical potential of Muzastotug, Adagene will supply the drug to Sanofi for a Phase I/II combination therapy clinical trial in patients with advanced solid tumors. The trial will assess the safety, efficacy, pharmacokinetics, and biomarkers of the combination, with an expected enrollment of over 100 patients. Adagene retains global commercial rights to Muzastotug.

In addition, Sanofi has initiated the third antibody development project under the SAFEbody® collaboration framework. This project will develop a bispecific antibody with an undisclosed target based on Adagene's proprietary safety masking technology and antibody engineering platform. According to the collaboration agreement signed in 2022, Sanofi will pay an option fee for this project, along with development milestone payments and tiered royalties based on sales as per the agreement.

As of December 31, 2024, Adagene's audited cash and cash equivalents were $85.2 million.Including Sanofi's investment in this round,AdagenePreFunding can support operations until 2027.According to the equity investment and strategic cooperation agreement, Sanofi will send a representative to join the Adagene Scientific Advisory Committee to provide strategic advice for Adagene's research and development work.

Cover Source:Corporate logo

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment options. If needed, please consult and contact正规医疗机构.

Editor: Xinyao

PR Article Coordination: WeChat insightxb